Journal for ImmunoTherapy of Cancer: 9 (9)

Basic tumor immunology

Original research: Loss of host tissue transglutaminase boosts antitumor T cell immunity by altering STAT1/STAT3 phosphorylation in ovarian cancer (30 September, 2021)
Livia Elena Sima, Siqi Chen, Horacio Cardenas, Guangyuan Zhao, Yinu Wang, Cristina Ivan, Hao Huang, Bin Zhang, Daniela Matei
Original research: Leveraging the Treg-intrinsic CTLA4–PKCη signaling pathway for cancer immunotherapy (29 September, 2021)
Hsin-Yu Liu, Christophe Pedros, Kok-Fai Kong, Ann J Canonigo-Balancio, Wen Xue, Amnon Altman
Original research: Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes (16 September, 2021)
Mikako Nishida, Nahoko Yamashita, Taisaku Ogawa, Keita Koseki, Eiji Warabi, Tomoyuki Ohue, Masaaki Komatsu, Hirokazu Matsushita, Kazuhiro Kakimi, Eiryo Kawakami, Katsuyuki Shiroguchi, Heiichiro Udono
Original research: GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma (6 September, 2021)
Zhaowei Wang, Lei He, Weina Li, Chuanyang Xu, Jieyu Zhang, Desheng Wang, Kefeng Dou, Ran Zhuang, Boquan Jin, Wei Zhang, Qiang Hao, Kuo Zhang, Wangqian Zhang, Shuning Wang, Yuan Gao, Jintao Gu, Lei Shang, Zhijun Tan, Haichuan Su, Yingqi Zhang, Cun Zhang, Meng Li
Original research: Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy (2 September, 2021)
James McAuliffe, Hok Fung Chan, Laurine Noblecourt, Ramiro Andrei Ramirez-Valdez, Vinnycius Pereira-Almeida, Yaxuan Zhou, Emily Pollock, Federica Cappuccini, Irina Redchenko, Adrian VS Hill, Carol Sze Ki Leung, Benoit J Van den Eynde

Clinical/translational cancer immunotherapy

Original research: Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. (30 September, 2021)
David J. Pinato, Sam M Murray, Alejandro Forner, Takahiro Kaneko, Petros Fessas, Pierluigi Toniutto, Beatriz Mínguez, Valentina Cacciato, Claudio Avellini, Alba Diaz, Rosemary J. Boyton, Daniel M. Altmann, Robert D Goldin, Ayse U Akarca, Teresa Marafioti, Francesco A Mauri, Edoardo Casagrande, Federica Grillo, Edoardo Giannini, Sherrie Bhoori, Vincenzo Mazzaferro
Original research: Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival (30 September, 2021)
Leonie K de Klerk, Anuj K Patel, Sarah Derks, Eirini Pectasides, Jeremy Augustin, Mohamed Uduman, Nihal Raman, Fahire G Akarca, Nadine J McCleary, James M Cleary, Douglas A Rubinson, Jeffrey W Clark, Bridget Fitzpatrick, Lauren K Brais, Megan E Cavanaugh, Amanda J Rode, Melissa G Jean, Patrick H Lizotte, Matthew J Nazzaro, Mariano Severgnini, Hui Zheng, Charles S Fuchs, Peter C Enzinger, Adam J Bass
Original research: Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade (27 September, 2021)
Takashi Yoshida, Chisato Ohe, Junichi Ikeda, Naho Atsumi, Haruyuki Ohsugi, Motohiko Sugi, Koichiro Higasa, Ryoichi Saito, Koji Tsuta, Tadashi Matsuda, Hidefumi Kinoshita
Elevated T cell repertoire diversity is associated with progression of lung squamous cell premalignant lesions (27 September, 2021)
Asaf Maoz, Carter Merenstein, Yusuke Koga, Austin Potter, Adam C Gower, Gang Liu, Sherry Zhang, Hanqiao Liu, Christopher Stevenson, Avrum Spira, Mary E Reid, Joshua D Campbell, Sarah A Mazzilli, Marc E Lenburg, Jennifer Beane
Original research: Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer (20 September, 2021)
Leyre Zubiri, Gabriel E Molina, Meghan J Mooradian, Justine Cohen, Sienna M Durbin, Laura Petrillo, Genevieve M Boland, Dejan Juric, Michael Dougan, Molly F Thomas, Alex T Faje, Michelle Rengarajan, Amanda C Guidon, Steven T Chen, Daniel Okin, Benjamin D Medoff, Mazen Nasrallah, Minna J Kohler, Sara R Schoenfeld, Rebecca K Leaf, Meghan E Sise, Tomas G Neilan, Daniel A Zlotoff, Jocelyn R Farmer, Aditya Bardia, Ryan J Sullivan, Steven M Blum, Yevgeniy R Semenov, Alexandra-Chloé Villani, Kerry L Reynolds
Original research: Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates (16 September, 2021)
John B Liao, William R Gwin, Renata R Urban, Katie M Hitchcock-Bernhardt, Andrew L Coveler, Doreen M Higgins, Jennifer S Childs, Hania N Shakalia, Ron E Swensen, Sasha E Stanton, Anna V Tinker, Tanya A Wahl, Richard G Ancheta, Kathryn F McGonigle, James Y Dai, Mary L Disis, Barbara A Goff
Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study (15 September, 2021)
Pankti Reid, David FL Liew, Rajshi Akruwala, Anne R Bass, Karmela K Chan
Original research: Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study (14 September, 2021)
Seongman Bae, Ye-Jee Kim, Min-ju Kim, Jwa Hoon Kim, Sung-Cheol Yun, Jiwon Jung, Min Jae Kim, Yong Pil Chong, Sung-Han Kim, Sang-Ho Choi, Yang Soo Kim, Sang-Oh Lee
Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab (13 September, 2021)
Landon C. Brown, Kunal Desai, Wei Wei, Emily N. Kinsey, Chester Kao, Daniel J. George, Brian I. Rini, Moshe C. Ornstein, Tian Zhang
Original research: Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma (12 September, 2021)
Eva Bräunlein, Gaia Lupoli, Franziska Füchsl, Esam T Abualrous, Niklas de Andrade Krätzig, Dario Gosmann, Lukas Wietbrock, Sebastian Lange, Thomas Engleitner, Huan Lan, Stefan Audehm, Manuel Effenberger, Melanie Boxberg, Katja Steiger, Yinshui Chang, Kai Yu, Cigdem Atay, Florian Bassermann, Wilko Weichert, Dirk H Busch, Roland Rad, Christian Freund, Iris Antes, Angela M Krackhardt
Original research: Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer (3 September, 2021)
Peter J DeMaria, Katherine Lee-Wisdom, Renee N Donahue, Ravi A Madan, Fatima Karzai, Angie Schwab, Claudia Palena, Caroline Jochems, Charalampos Floudas, Julius Strauss, Jennifer L Marté, Jason Mark Redman, Eva Dombi, Brigitte Widemann, Borys Korchin, Tatiana Adams, Cesar Pico-Navarro, Christopher Heery, Jeffrey Schlom, James L Gulley, Marijo Bilusic
Original research: Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer (2 September, 2021)
Carmine Carbone, Geny Piro, Antonio Agostini, Pietro Delfino, Francesco De Sanctis, Vincenzo Nasca, Francesco Spallotta, Claudio Sette, Maurizio Martini, Stefano Ugel, Vincenzo Corbo, Paola Cappello, Emilio Bria, Aldo Scarpa, Giampaolo Tortora
Original research:
High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4⁺ and CD8⁺ neoantigen-specific T cells to promote antitumor immunity
(2 September, 2021)
Rosmely Hernandez, Kathryn M LaPorte, Sunnie Hsiung, Alicia Santos Savio, Thomas R Malek

Commentary

Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov (28 September, 2021)
Yi Que, Yang Hu, Dongchun Hong, Yizhuo Zhang

Immunotherapy biomarkers

Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma (30 September, 2021)
Robin Reschke, Jovian Yu, Blake A Flood, Emily F Higgs, Ken Hatogai, Thomas F Gajewski
Original research:
CD8⁺ TILs in NSCLC differentiate into TEMRA via a bifurcated trajectory: deciphering immunogenicity of tumor antigens
(30 September, 2021)
Sung-Woo Lee, He Yun Choi, Gil-Woo Lee, Therasa Kim, Hyun-Ju Cho, In-Jae Oh, Sang Yun Song, Deok Hwan Yang, Jae-Ho Cho
Original research: Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma (23 September, 2021)
Doreen Lau, Mary A McLean, Andrew N Priest, Andrew B Gill, Francis Scott, Ilse Patterson, Bruno Carmo, Frank Riemer, Joshua D Kaggie, Amy Frary, Doreen Milne, Catherine Booth, Arthur Lewis, Michal Sulikowski, Lee Brown, Jean-Martin Lapointe, Luigi Aloj, Martin J Graves, Kevin M Brindle, Pippa G Corrie, Ferdia A Gallagher
Original research: DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer (21 September, 2021)
Qi Zou, Xiaolin Wang, Donglin Ren, Bang Hu, Guannan Tang, Yu Zhang, Meijin Huang, Rish K Pai, Daniel D Buchanan, Aung Ko Win, Polly A Newcomb, William M Grady, Huichuan Yu, Yanxin Luo
Original research: Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers (3 September, 2021)
Jieer Ying, Lin Yang, Jiani C Yin, Guojie Xia, Minyan Xing, Xiaoxi Chen, Jiaohui Pang, Yong Wu, Hua Bao, Xue Wu, Yang Shao, Lingjun Zhu, Xiangdong Cheng

Immune cell therapies and immune cell engineering

Original research: Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design (16 September, 2021)
Haiying Qin, Lila Yang, John A Chukinas, Nirali N Shah, Samiksha Tarun, Marie Pouzolles, Christopher D Chien, Lisa M Niswander, Anthony R Welch, Naomi A Taylor, Sarah K Tasian, Terry J Fry
Original research: Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells (12 September, 2021)
Justin T Huckaby, Elisa Landoni, Timothy M Jacobs, Barbara Savoldo, Gianpietro Dotti, Samuel K Lai
Original research: Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy (8 September, 2021)
Tsung-Yi Lin, Jeong A Park, Alan Long, Hong-Fen Guo, Nai-Kong V Cheung

Oncolytic and local immunotherapy

Original research: Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia (30 September, 2021)
Weiyi Wang, Shuaitong Liu, Peihong Dai, Ning Yang, Yi Wang, Rachel A Giese, Taha Merghoub, Jedd Wolchok, Liang Deng
Original research: Simple and effective bacterial-based intratumoral cancer immunotherapy (16 September, 2021)
Christina S E Carroll, Erin R Andrew, Laeeq Malik, Kathryn F Elliott, Moira Brennan, James Meyer, Alexander Hintze, Andrew A Almonte, Cassandra Lappin, Philip MacPherson, Klaus-Martin Schulte, Jane E Dahlstrom, Rohit Tamhane, Teresa Neeman, Elizabeth W Herbert, Maurice Orange, Desmond Yip, Rachel Allavena, Aude M Fahrer
Original research: Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity (16 September, 2021)
Clément Anfray, Francesco Mainini, Elisabeth Digifico, Akihiro Maeda, Marina Sironi, Marco Erreni, Achille Anselmo, Aldo Ummarino, Sara Gandoy, Francisco Expósito, Miriam Redrado, Diego Serrano, Alfonso Calvo, Marvin Martens, Susana Bravo, Alberto Mantovani, Paola Allavena, Fernando Torres Andón

Position article and guidelines

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma (12 September, 2021)
Tim F Greten, Ghassan K Abou-Alfa, Ann-Lii Cheng, Austin G Duffy, Anthony B. El-Khoueiry, Richard S Finn, Peter R Galle, Lipika Goyal, Aiwu Ruth He, Ahmed O Kaseb, Robin Kate Kelley, Riccardo Lencioni, Amaia Lujambio, Donna Mabry Hrones, David J Pinato, Bruno Sangro, Roberto I Troisi, Andrea Wilson Woods, Thomas Yau, Andrew X Zhu, Ignacio Melero

Review

Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy (13 September, 2021)
James Harber, Tamihiro Kamata, Catrin Pritchard, Dean Fennell
Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR (3 September, 2021)
Nicholas L Bayless, Jeffrey A Bluestone, Samantha Bucktrout, Lisa H Butterfield, Elizabeth M Jaffee, Christian A Koch, Bart O Roep, Arlene H Sharpe, William J Murphy, Alexandra-Chloé Villani, Theresa L Walunas

Main menu

Table of contents

September 2021 - Volume 9 - 9

Basic tumor immunology

Clinical/translational cancer immunotherapy

Commentary

Immunotherapy biomarkers

Immune cell therapies and immune cell engineering

Oncolytic and local immunotherapy

Position article and guidelines

Review

Correction

Log in using your username and password

Main menu

Log in using your username and password

You are here

Table of contents

September 2021 - Volume 9 - 9

Basic tumor immunology

Clinical/translational cancer immunotherapy

Commentary

Immunotherapy biomarkers

Immune cell therapies and immune cell engineering

Oncolytic and local immunotherapy

Position article and guidelines

Review

Correction